CPD Points For Professionals

CPD Points For Professionals

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

High Quality Portfolio Stocks

High Quality Portfolio Stocks

To read the full report … Login Here

Australian Dollar Outlook Futures

Australian Dollar Outlook Futures

To read the full report … Login Here

Small Cap Russell Record

Small Cap Russell Record

To read the full report … Login Here

Warren Buffett Valuation Ratio

Warren Buffett Valuation Ratio

To read the full report … Login Here

Brazilian Rare Earths (BRE)

Brazilian Rare Earths (BRE)

To read the full report … Login Here

Visa (V) Valuation and Analysis

Visa (V) Valuation and Analysis

To read the full report … Login Here

Past Results of Australian Funds

Past Results of Australian Funds

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

BHP, Nickel, Iron Ore and China

BHP, Nickel, Iron Ore and China

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

How To Get Your Dream Job

How To Get Your Dream Job

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

Macquarie Bank Hires Teenager

Macquarie Bank Hires Teenager

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

Diploma of Company Analysis

Diploma of Company Analysis

Marcus Tuck

Head of Research

7.00 am 7 August 2020

The sleep apnea medical device company ResMed (ASX:RMD) is an Australian large-cap global success story with impressive long-term share price performance and a solid track record of profit and free cash flow growth to back it up. However, ResMed’s share price fell 7.4% yesterday after delivering its profit results for the June quarter and the full year FY20. What went wrong and, more importantly, is the stock’s impressive run ending?

Now headquartered in San Diego, ResMed’s digital health technologies and cloud-connected medical devices have transformed care for people with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.

To read the full report … Login Here

Register for our FREE reports here...

You have Successfully Subscribed!

Register for our FREE reports here...

You have Successfully Subscribed!